DUBLIN--(BUSINESS WIRE)--The "Global Idiopathic Thrombocytopenic Purpura Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
According to the report, one driver influencing this market is the increasing second- and third-line therapies. The global ITP therapeutics market is witnessing an increase in the inflow of second and third-line therapies to meet the unmet needs of ITP.
Further, the report states that one challenge affecting this market is the side effects of approved treatment. Many approved therapeutics cause serious side effects which is a key challenge in the global ITP therapeutics market.
Key Vendors
- Amgen
- Bristol-Myers Squibb
- Eisai
- Merck Sharp & Dohme
- Novartis
Topics Covered
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Product
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
11. Market Trends
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/g4q6xp/global_idiopathic?w=4